During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
News|Articles|September 1, 2011
Formulary Digital Edition September 2011
Management of chronic obstructive pulmonary disease: An emphasis on recently approved medications and products in the pipeline; Focus On Boceprevir: A new oral protease inhibitor for the treatment of chronic hepatitis C
Advertisement
Advertisement
Related to this article
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
More pluses for GLP-1s for obstructive sleep apnea | CHEST 2026
2
Long-acting lenacapavir plus cabotegravir kept all 46 patients with HIV virally suppressed in recent trial
3
Experts say cost barriers and stigma keep eligible adults from lung cancer screening
4
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
5